Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-05-24
2005-05-24
Dodson, Shelley A. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S169000, C514S170000, C514S825000, C514S826000, C514S863000, C514S866000
Reexamination Certificate
active
06897206
ABSTRACT:
The invention features a method for treating a patient having an inflammatory disorder, by administering to the patient (i) a tricyclic antidepressant (e.g., amoxapine); and (ii) a corticosteroid (e.g., prednisolone) simultaneously or within 14 days of each other in amounts sufficient to reduce or inhibit inflammation.
REFERENCES:
patent: 4034087 (1977-07-01), Voorhees
patent: 4107306 (1978-08-01), Voorhees
patent: 5900249 (1999-05-01), Smith
Berberian et al., The Adiition of Topical Doxepin to Corticosteroid Therapy: An Improved Treatment Regimen for Atopic Dermatitis, International Journal of Dermatology 38:145-148 (1999).*
Ash et al., “The Effects of Dothiepin on Subjects with Rheumatoid Arthritis and Depression,”Rheumatology38:959-967 (1999).
Barden, “Regulation of Corticosteroid Receptor Gene Expression in Depression and Antidepressant Action,”Journal of Psychiatry and Neuroscience24:25-39 (1999).
Berberian et al., “The Addition of Topical Doxepin to Corticosteroid Therapy: An Improved Treatment Regimen for Atopic Dermatitis,”International Journal of Dermatology38:145-148 (1999).
Bird and Broggini, “Paroxetine Versus Amitriptyline for Treatment of Depression Associated with Rheumatoid Arthritis: A Randomized, Double Blind, Parallel Group Study,”The Journal of Rheumatology2791-2797 (2000).
Bresnihan, “Treatment of Rheumatoid Arthritis with Interleukin 1 Receptor Antagonist,”Annals of Rheumatoid Disorders58:196-198 (1999).
Budziszewska et al., “Antidepressant Drugs Inhibit Glucocorticoid Receptor-Mediated Gene Transcription- A Possible Mechanism,”British Journal of Pharmacology130:1385-1393 (2000).
Calvo et al., “Pharmacokinetics of Amoxapine and its Active Metabolites,”International Journal of Clinical Pharmacology, Therapy, and Toxicology23:180-185 (1985).
Carty et al., “The Biochemistry and Pharmacology of TNFα and β, Apr. 21, 1995, New York,”Inflammation Research44:455-457 (1995).
Chuck et al., “The Effects of Dothiepin on Subjects with Rheumatoid Arthritis and Depression,”Rheumatology39:1425-1427 (2000).
Clark, “Chronic Pain, Depression, and Antidepressants: Issues and Relationships,” Johns Hopkins Arthritis Website: http://www.hopkins-arthritis.som.jhml.edu/mngmnt/depression.html, Oct. 4, 2002.
Coupet et al., “The Effects of 2-chloro-11-(4-methyl-l-piperazinyl)-dibenz[b,f] [1,4]oxazepine (loxapine) and its Derivatives on the Dopamine-Sensitive Adenylate Cyclase of Rat Striatal Homogenates,”Brain Research116:177-180 (1976).
Didonato et al., “Molecular Mechanisms of Immunosuppression and Anti-inflammatory Activities by Glucocorticoids,”American Journal of Respiratory and Critical Care Medicine154:S11-S15 (1996).
Ehrenstein, “Combination Therapy in Rheumatoid Arthritis,”British Journal of Rheumatology34:580-581 (1995).
Fishbain, “Evidence-based Data on Pain Relief with Antidepressants,”Annals of Medicine32:305-316 (2000).
Fowler et al., “Imipramine, Rheumatoid Arthritis and Rheumatoid Factor,”Current Medical Research and Opinion5:241-246 (1977).
Frank et al., “Antidepressant Analgesia in Rheumatoid Arthritis,”The Journal of Rheumatology15:1632-1638 (1988).
Godefroy et al., “Do Acute or Chronic Tricyclic Antidepressants Modify Morphine Antinociception in Arthritic Rats?”Pain25:233-244 (1986).
Gupta et al., “Antidepressant Drugs in Dermatology,”Archives of Dermatology123:647-652 (1987).
Gupta and Gupta, “The use of Antidepresant Drugs in Dermatology,”Journal of European Academy of Dermatology and Venereology15:512-518 (2001).
Healey and Wilske, “Evaluating Combination Drug Therapy in Rheumatoid Arthritis,”Journal of Rheumatology18:641-642 (1991).
Hinze-Selch et al., “Effects of Antidepressants on Weight and on the Plasma Levels of Leptin, TNF-α and Soluble TNF Receptors: A Longitudinal Study in Patients Treated with Amitriptyline or Paroxetine,”Neuropsychopharmacology23:13-19 (2000).
Holsboer, “The Corticosteroid Receptor Hypothesis of Depression,”Neuropsychopharmacology23:477-501 (2000).
Jue et al., “Amoxapine: A Review of its Pharmacology and Efficacy in Depressed States,”Drugs24:1-23 (1982).
Kirwan, “Systemic Low-dose Glucocorticoid Treatment in Rheumatoid Arthritis,”Rheumatoid Arthritis27:389-403 (2001).
Koh et al., “Low Dose Amitriptyline in Ankylosing Spondylitis: A Short Term, Double Blind, Placebo Controlled Study,”The Journal of Rheumatology24:2158-2161 (1997).
Kristensen, “Plasma Protein Binding of Imipramine in Patients with Rheumatoid Arthritis,”European Journal of Clinical Pharmacology28:693-696 (1985).
Kubera et al., “Effect of Repeated Desipramine and Fluoxetine Administration on Post-Adjuvant Arthritis,”Polish Journal of Pharmacology52:229-235 (2000).
Lanquillon et al., “Cytokine Production and Treatment Response in Major Depressive Disorder,”Neuropsychopharmacology22:370-379 (2000).
Lee et al., “Effect of Steroids on the Inhibition of Platelet 5HT Uptake by Desipramine and Other Antidepressants,”European Journal of Pharmacology106:255-262 (1985).
Lydiard et al., “Amoxapine—An Antidepressant with Some Neuroleptic Properties? A Review of its Chemistry, Animal Pharmacology and Toxicology, Human Pharmacology, and Clinical Efficacy,”Pharmacotherapy1:163-178 (1981).
Macfarlane et al., “Trimipramine in Rheumatoid Arthritis: A Randomized Double-Blind Trial in Relieving Pain and Joint Tenderness,”Current Medical Research and Opinion10:89-93 (1986).
MacNeill et al., “Imipramine and Rheumatoid Factor,”Journal of International Medical Research4:23-27 (1976).
Maes et al., “Negative Immunoregulatory Effects of Antidepressants: Inhibition of Interferon-γ and Stimulation of Interleukin-10 Secretion,”Neuropsychopharmacology20:370-379 (1999).
Maes, “Major Depression and Activation of the Inflammatory Response System,”Advances in Experimental Medicine and Biology461:25-46 (1999).
Maes et al., “Effects of Atypical Antipsychotics on the Inflammatory Response System in Schizophrenic Patients Resistant to Treatment with Typical Neuroleptics,”European Neuropsychopharmacology10:119-124 (2000).
Magni, “The Use of Antidepressants in the Treatment of Chronic Pain,”Drugs42:730-948 (1991).
Martelli et al., “Mechanism of Inhibition of Experimental Inflammation by Antidepressant Drugs,”European Journal of Pharmacology2:229-233 (1967).
Mastaglia, “Adverse Effects of Drugs on Muscle,”Drugs24:304-321 (1982).
McBride et al., “Management of Rheumatoid Arthritis,”Southern Medical Journal307-314 (1969).
McLain, “Rheumatoid Arthritis—Update on New Therapies,”Southern Medical Journal94:893-895 (2001).
Michelson et al., “Imipramine Reduces the Local Inflammatory Response to Carrageenin,”Agents Actions42:25-28 (1994).
Morris, “Combination Drug Therapy in Rheumatoid Arthritis,”The Journal of Rheumatology23:1113 (1996).
Okugawa et al., “Long-Term Treatment with Antidepressants Increases Glucocorticoid Receptor Binding and Gene Expression in Cultured Rat Hippocampal Neurones,”Journal of Neuroendocrinology11:887-895 (1999).
Pariante et al., “Steroid-Independent Translocation of the Glucocorticoid Receptor by the Antidepressant Desipramine,”Molecular Pharmacology52:571-581 (1997).
Petitto et al., “Improvement of Arthritis with Fluoxetine,”Psychosomatics338-341.
Pullar, “Combination Therapy in Rheumatoid Arthritis,”British Journal of Rheumatology30:311-312 (1991).
Puttini et al., “A Comparison of Dothiepin Versus Placebo in the Treatment of Pain in Rheumatoid Arthritis and the Association of Pain with Depression,”Journal
Borisy Alexis
Fong Jason
Hurst Nicole
Jost-Price Edward Roydon
Keith Curtis
Clark & Elbing LLP
CombinatoRx, Inc.
Dodson Shelley A.
George Konata M.
LandOfFree
Combinations for the treatment of inflammatory disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combinations for the treatment of inflammatory disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations for the treatment of inflammatory disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3411942